SCHEMBL2215002

SCHEMBL2215002

CC(=O)Nc1cccc(-c2ccc(-c3cc4ccnn4c(Nc4ccc(NC(=O)c5ccc(CN)cc5)cc4)n3)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.45
POLB P06746 1/20 0.45
MCL1 Q07820 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP17A1 P05093 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
PTGIR P43119 2/20 0.42
KIT P10721 1/20 0.42
PDGFRA P16234 1/20 0.42
HDAC1 Q13547 5/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215099 0.96 POLB (0.47) JAK2POLBMCL1TDP1CYP17A1
SCHEMBL2214475 0.94 JAK2 (0.43) JAK2POLBMCL1TDP1CYP17A1
SCHEMBL2211981 0.91 HDAC1 (0.45) POLBKITPDGFRAHDAC1MEN1
SCHEMBL2214363 0.89 HDAC1 (0.42) KITPDGFRAHDAC1MEN1KMT2A
SCHEMBL2214589 0.88 HDAC1 (0.45) POLBKITPDGFRAHDAC1MAPT
SCHEMBL2215189 0.88 PLAU (0.50) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL2881428 0.87 FYN (0.51) POLBCYP17A1CYP11B1CYP11B2MEN1
SCHEMBL2215297 0.87 PTPN1 (0.45) POLBTDP1MEN1KMT2AALDH1A1
SCHEMBL2214607 0.86 PLAU (0.46) POLBMEN1KMT2AALDH1A1MAPT
SCHEMBL2212378 0.86 SNCA (0.49) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 JAK2 914/4885POLB 828/4885MCL1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.